The Neuroscience Graduate Program was on (Galveston) island time this week! Had a great retreat hearing from research award winners, faculty members in workshops, and NGP alumni 🏖️ 🧠 🌊 🥼 🎉
Congrats to the 2024 GSRD contest winners! And thanks to all the attendees and participants for making this a great event! A story recapping GSRD with a full list of winners & event photos will be posted on https://t.co/SQpMNjcm2A next week. #WeAreGSBS#EndCancer#UTHealthHouston
CNN report on the potential of semaglutide for addictive behaviors, featuring our own @Lorenzo__Leggio:
https://t.co/TmWxHBQpwq
@CNN@NIDAnews @NIAAAnews @IRPatNIH
Thanks/kudos to co-first authors @VickyChuong & @sophia_khom, plus everyone else who made this #teamscience possible: @claire_pince @RenataMarchette @Lorenzo__Leggio & Twitterless folks.
More to come, e.g., an RCT 👇, population studies, non-alcohol drugs, and other GLP-1 meds!
🚨 The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission 🚨
Super excited to see this FINALLY out in @JCI_insight.
https://t.co/T5UDRs7Fpe
⚠️ Preview version
@NIDAnews @NIAAAnews @IRPatNIH@scrippsresearch
iGluSnFR3 is published! Check it out⬇️
https://t.co/hQC58oNxj2
We made a new glutamate indicator with improved sensitivity, kinetics & localization for imaging synaptic transmission.
This is #iGluSnFR3 in action detecting minis w/ TTX.
@PodgorskiLab@HHMIJanelia@AllenInstitute
Shameless self (and coauthors) promotion.
NIDA featured paper of the month.
#TeamScience@DarthCTR@VickyChuong@Lorenzo__Leggio
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies
https://t.co/0C6phg4cvE
Are you attending the #SfN2022 and interested in decision making, approach-avoidance conflict, USVs and corticothalamic circuits? Stop by our posters on Sun and Tue PM to learn from our talented students @xuzhang95@CanaQuave@VickyChuong@claireeuncho and others. 🐀🧀🐈⬛⚡️🎼🧠